2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

2:30PM-4:00PM: Abstract Number: 2798

Expanded T-Cell Clones Are Present in the Synovium before the Clinical Onset of Rheumatoid Arthritis

5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

2:30PM-4:00PM: Abstract Number: 2846

Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants

5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

2:30PM-4:00PM: Abstract Number: 2810

Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate

5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

2:30PM-4:00PM: Abstract Number: 2818

Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis

5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

2:30PM-4:00PM: Abstract Number: 2831

High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis

5T091 ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Comorbid/Related Conditions(2826–2831)

2:30PM-4:00PM: Abstract Number: 2804

Identifying Lupus Patients in Electronic Health Records: Development and Validation of Machine Learning Algorithms and Application of Rule-Based Algorithms

5T086 ACR Abstract: Epidemiology & Pub Health III: SLE & SSc, Big Data & Large Cohorts (2802–2807)

2:30PM-4:00PM: Abstract Number: 2795

IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus

5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)

2:30PM-4:00PM: Abstract Number: 2843

Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience

5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

2:30PM-4:00PM: Abstract Number: 2836

Measurement of Interferon Alpha Expression Using Multiple Methodologies Identifies a Signature in a Subgroup of Connective Tissue Disease Patients with Haematological Abnormalities

5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

2:30PM-4:00PM: Abstract Number: 2814

Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs

5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

2:30PM-4:00PM: Abstract Number: 2839

Microrna Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis

5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

2:30PM-4:00PM: Abstract Number: 2840

MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination

5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

2:30PM-4:00PM: Abstract Number: 2793

Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis

5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)

2:30PM-4:00PM: Abstract Number: 2832

Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2

5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

2:30PM-4:00PM: Abstract Number: 2824

On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering

5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].